CCMP Confirms Buy of Medpace, Deal Valued at Roughly $500 Mln
CCMP Capital Advisors is buying 80% of Medpace via a recap. Management will own the rest, according to a statement Monday. News of the deal was reported by peHUB last week. The transaction is valued at roughly $500 million, a person said. Cincinnati-based Medpace is a CRO that provides Phase I-IV core development services for drug, biologic, and device programs.
23 May 2011•2 mins read
